InvestorsHub Logo
Followers 21
Posts 1400
Boards Moderated 0
Alias Born 03/03/2021

Re: Bright Boy post# 447566

Tuesday, 03/01/2022 3:45:34 PM

Tuesday, March 01, 2022 3:45:34 PM

Post# of 695564
A tad Mis-leading from DI .. or poster

The phrase "treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both North America and Europe” Attributed to recent LPOW UK interviews, well... see nwbio.com press release "about Northwest Biotherapeutics"

You will see this... (I only went back to 05/12/2021 PR)

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing personalized immunotherapy products designed to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both North America and Europe. The Company has a broad platform technology for DCVax® dendritic cell-based vaccines. The Company’s lead program is a 331-patient Phase III trial of DCVax®-L for newly diagnosed Glioblastoma multiforme (GBM). GBM is the most aggressive and lethal form of brain cancer, and is an “orphan disease.” This Phase III trial is now completed, with the trial data now being analyzed. The Company is also pursuing development of DCVax®-Direct for inoperable solid tumor cancers. It has completed a 40-patient Phase I trial and, as resources permit, is preparing for Phase II trials. The Company previously conducted a Phase I/II trial with DCVax-L for advanced ovarian cancer together with the University of Pennsylvania.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News